Table 10 Laboratory adverse experiences occurring at an incidence rate of ≥1% in any group
From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Adverse Experience | Sitagliptin 100 mg n/N (%) | Non-Exposed n/N (%) | Difference between Sitagliptin and Non-Exposed, % (95% CI)* |
|---|---|---|---|
Alanine Aminotransferase Increased | 51/3365 (1.5) | 37/2672 (1.4) | 0.1 (-0.5, 0.7) |
Aspartate Aminotransferase Increased | 35/3365 (1.0) | 26/2672 (1.0) | 0.1 (-0.5, 0.6) |
Blood Uric Acid Increased | 37/3364 (1.1) | 22/2672 (0.8) | 0.3 (-0.2, 0.8) |
Creatine Phosphokinase Increased | 22/819 (2.7) | 11/619 (1.8) | 0.9 (-0.7, 2.5) |
Creatinine Clearance Estimation Decreased | 31/3243 (1.0) | 14/2551 (0.5) | 0.4 (-0.1, 0.9) |
Fasting Blood Glucose Increased | 52/3370 (1.5) | 63/2675 (2.4) | -0.8 (-1.6, 0.1) |
Low Density Lipoprotein Increased | 5/185 (2.7) | 2/169 (1.2) | 1.5 (-1.9, 5.1) |
Protein Urine Present | 19/1541 (1.2) | 7/1209 (0.6) | 0.7 (-0.1, 1.4) |
Urine Microalbumin Present | 2/228 (0.9) | 9/251 (3.6) | -2.7 (-5.9, 0.1) |